20Staphylococcus aureus is a notorious bacterial pathogen that often causes soft tissue 21 and bloodstream infections and invariably garners resistance mechanisms against new 22 antibiotics. Host innate immunity modulated by metabolites has been proved as a 23 powerful strategy against bacterial infections. However, few studies focus on the 24 application of this strategy against S. aureus infection. Here, we identified four metabolite 25 biomarkers, L-proline, L-isoleucine, L-leucine, and L-valine (PILV), by a metabolomics 26 study. In animal models of S. aureus bloodstream infection, exogenous administration of 27 each metabolite or PILV shows an anti-infective effect, while PILV treatment has higher 28 protection than individual metabolite treatment. Each metabolite targets nitric oxide (NO) 29 to kill S. aureus via arginase inhibition, and PILV exhibits additive inhibition of arginase 30 activity that causes further killing. This suppression also contributes to the 31 metabolite-mediated phagocytic killing of S. aureus in human blood. Our finding 32 demonstrates the metabolite-mediated innate immunity as a therapeutic intervention for 33 S. aureus infection. 34 35 Keywords: metabolite, Staphylococcus aureus, bloodstream infection, nitric oxide, 36 arginase, 37 38The pathogen Staphylococcus aureus is both a human commensal and a significant 39 cause of hospital-and community-acquired diseases including soft tissue infections, 40 pneumonia, osteomyelitis, septic arthritis, bacteremia, endocarditis, and sepsis (1-3). The 41 asymptomatic colonization is common; however, 80% invasive S. aureus strains isolated 42 from the blood of patients with S. aureus bacteremia are genetically indistinguishable to 43 the nasal strains detected at admission (4). Because of the high incidence of 44 hospital-acquired infection, antibiotics are employed both for S. aureus decolonization 45 and prophylaxis of nosocomial disease (5, 6). However, the emergence and spread of 46 drug-resistant strains, designated MRSA (methicillin-resistant S. aureus), led to 47 increased therapeutic failure and mortality rates due to S. aureus infections (6). Therefore, 48 new approaches are especially needed for treating such infections in the clinic. One 49 possible approach would be to enhance the innate immune response of the infected host, 50 restoring the defense ability to kill the bacterial pathogen in a relatively risk-free manner 51 (7). 52 53 Similar to other bacterial infections (8, 9), S. aureus infection causes several metabolisms 54 changed pronouncedly in the host, which contain oxidative phosphorylation, aerobic 55 glycolysis, and amino acid and fatty acid metabolisms (10)(11)(12)(13)(14). A growing body of recent 56 studies shows that bacterial infection-induced shift of metabolisms has two leading roles, 57 which either facilitate the bacterial invasion or benefits to the immune responses against 58 bacterial infection. Host central carbon metabolism is capable of being strongly disturbed 59 by S. aureus, which activates autophagy b...